HCPCS Code S0189: Testosterone Pellet, 75 mg

Bill HCPCS S0189 accurately. Learn documentation, billing, and coverage rules for testosterone pellet implants to avoid denials.

Use Code

## **What is testosterone pellet therapy?** HCPCS code S0189 describes a testosterone pellet implant, 75 mg, used as part of testosterone therapy in carefully selected patients. These pellets are inserted subcutaneously, usually in the buttock or hip, and provide a long-acting, steady release of testosterone over several months. This method is one of several forms of testosterone replacement therapy (TRT) or hormone replacement therapy (HRT), and is billed separately from the implantation procedure. Pellet therapy is most often prescribed for men with primary or secondary hypogonadism, including conditions such as testicular failure or pituitary-hypothalamic injury, where the body does not produce sufficient testosterone. In these cases, pellets function as a form of androgen replacement therapy or androgen therapy, helping to restore normal hormone levels, improve energy, libido, and muscle mass, and reduce symptoms linked to testosterone deficiency. Unlike synthetic testosterone derivatives given by injection or topical gels, pellets release hormone consistently, reducing the peaks and troughs that can occur with shorter-acting regimens. This stable dosing profile makes them attractive to some patients and providers managing long-term testosterone replacement therapy. However, pellet therapy and other forms of androgen therapy are not without risk. Improper use, especially in the setting of anabolic androgenic steroid abuse or testosterone abuse, can lead to serious adverse health effects, including major adverse cardiovascular events, psychiatric adverse reactions, and serious adverse reactions involving the liver and endocrine system. Even in medically supervised settings, complications may occur, such as implant site infection or irritation at the insertion area. Because of these risks, testosterone pellets should only be used under close medical supervision, with monitoring for both clinical benefits and potential harms. Careful patient selection, particularly in those with documented primary hypogonadism or secondary hypogonadism, is essential to ensure safe and effective androgen replacement therapy.

## **S0189 documentation requirements** Accurate and complete documentation is essential when billing for testosterone pellet therapy, since payers often scrutinize hormone replacement claims. Records must clearly show that the patient has a qualifying diagnosis, that alternative treatment options were considered, and that the service was provided safely and appropriately. ### **Prescription and diagnosis** Keep a signed prescription or Standard Written Order (SWO) that specifies testosterone pellet 75 mg, the intended dosage, and frequency. The order must be linked to an appropriate diagnosis, such as primary hypogonadism, secondary hypogonadism, or testicular failure. ### **Medical necessity** Chart notes should describe the patient’s symptoms of testosterone deficiency (fatigue, low libido, muscle loss, etc.) along with supporting lab results such as low serum testosterone levels on two separate morning draws. The rationale for choosing pellet therapy over other forms of androgen replacement therapy (injections, gels, patches) should also be documented. ### **Procedure note** The operative or procedure note should specify the site of implantation, the number of pellets inserted, and the total milligram dosage administered. Any complications, such as bleeding or implant site reaction, should also be recorded. ### **Product details** Document the lot number, manufacturer, strength, and quantity of pellets used. Retain invoices and proof of supply for audit purposes, and keep all records in line with Medicare Program Integrity Manual standards.

## **S0189 billing requirements** Billing for S0189 must align with payer policy and clearly separate the drug cost from the implantation procedure. Claims that lack detail about medical necessity or dosage are at higher risk of denial. ### **Units** Bill per 75 mg pellet supplied. For example, if four pellets (300 mg total) are implanted, submit 4 units of S0189. Always confirm that the units reported match the number documented in the procedure note. ### **Separate procedure billing** The pellet insertion procedure is billed separately using CPT 11980 (Under Introduction or Removal Procedures on the Integumentary System). Do not combine the drug and the procedure into a single line item. ### **Coverage considerations** Medicare generally does not cover testosterone pellets, often categorizing them as a self-administered drug. Some commercial insurers may cover S0189 if documentation demonstrates medical necessity and prior authorization was obtained. Coverage can vary significantly, so confirm the payer’s policy before treatment. ### **Medicare and payer review** Payers, including Medicare Administrative Contractors (MACs), may request records during audits. Be ready to provide lab values, chart notes, procedure documentation, and product information. Common denial reasons include missing hypogonadism diagnosis, insufficient laboratory evidence, or unclear dosing justification.

## **S0189 applicable modifiers** HCPCS code S0189 generally does not have specific Level II modifiers tied to its use. In practice, the need for modifiers depends on payer requirements: - Medicare often does not accept S0189 for testosterone pellets, particularly compounded products, and may require billing under J3490 (unclassified drug) instead. In these cases, detailed documentation of the drug name, strength, dosage, and route is essential. - Private insurers may accept S0189 directly, usually without additional modifiers, as long as the claim is linked to a qualifying diagnosis such as E29.1 (hypogonadism).

## **Other relevant HCPCS and CPT codes** - **J1071** – Injection, testosterone cypionate, 1 mg - **J3121** – Injection, testosterone enanthate, 1 mg

Frequently asked questions

No. Medicare does not reimburse S0189. For Medicare beneficiaries, testosterone pellets should be billed under J3490 (unclassified drug) with full clinical details and NDC information included.

Bill one unit per 75 mg pellet. For example, if six pellets are implanted, report six units of S0189 along with CPT 11980 for the implantation procedure.

Yes, many commercial payers require prior authorization. Plans such as Blue Shield often request documentation of testosterone deficiency, evidence of failed or intolerant response to injections or topical formulations, and proper diagnostic coding before approval.